Intellia Therapeutics, based in Cambridge, Massachusetts, reported promising results from the Phase II clinical trial of NTLA-2002, a CRISPR-based therapy targeting hereditary angioedema (HAE), a
Alnylam Pharmaceuticals, which specializes in developing RNA interference (RNAi) therapeutics to treat genetic diseases, has announced promising clinical trial results for their drug Amvuttra® (vutrisiran)
When CRISPR was discovered in 1987, it transformed biotech by offering a way to target genetic diseases thought to be untreatable. Although it has versatile
RNA editing is emerging as a promising and potentially safer alternative to therapies that modify an individual’s DNA. In December 2023, patients were treated in
In November 2023, the U.S. Food and Drug Administration (FDA) announced an investigation into chimeric antigen receptor (CAR) T-cell therapies, questioning if these promising cancer
Gene therapy continues to emerge as a promising approach in the treatment and prevention of a wide range of disorders and diseases. Central to the
Gene therapy has revolutionized the field of medical research by offering potential treatments for genetic disorders and diseases previously considered untreatable or incurable. A key
Recent years have seen increased research interest in the potential of chimeric antigen receptor (CAR)-T cancer therapies. This approach uses genetic engineering to modify T
Research results published in Nature this month demonstrate that chimeric antigen receptor (CAR) T-cell therapy, which uses engineered T-cells to target cancer, held leukemia at
CAR-T is an immunotherapy that is currently used to treat blood cancers and is in clinical trials to treat other cancers as well. This treatment
Transthyretin amyloidosis (ATTR amyloidosis) is a rare but fatal disease marked by clumping and accumulation of mutated, misfolded transthyretin proteins in peripheral nerves and cardiac
A common refrain in science fiction movies is the cautionary statement, “Just because we can doesn’t mean we should.” As new technologies such as CRISPR/Cas9
Intellia Therapeutics, based in Cambridge, Massachusetts, reported promising results from the Phase II clinical trial of NTLA-2002, a CRISPR-based therapy targeting hereditary angioedema (HAE), a
Alnylam Pharmaceuticals, which specializes in developing RNA interference (RNAi) therapeutics to treat genetic diseases, has announced promising clinical trial results for their drug Amvuttra® (vutrisiran)
When CRISPR was discovered in 1987, it transformed biotech by offering a way to target genetic diseases thought to be untreatable. Although it has versatile
RNA editing is emerging as a promising and potentially safer alternative to therapies that modify an individual’s DNA. In December 2023, patients were treated in
In November 2023, the U.S. Food and Drug Administration (FDA) announced an investigation into chimeric antigen receptor (CAR) T-cell therapies, questioning if these promising cancer
Gene therapy continues to emerge as a promising approach in the treatment and prevention of a wide range of disorders and diseases. Central to the
Gene therapy has revolutionized the field of medical research by offering potential treatments for genetic disorders and diseases previously considered untreatable or incurable. A key
Recent years have seen increased research interest in the potential of chimeric antigen receptor (CAR)-T cancer therapies. This approach uses genetic engineering to modify T
Research results published in Nature this month demonstrate that chimeric antigen receptor (CAR) T-cell therapy, which uses engineered T-cells to target cancer, held leukemia at
CAR-T is an immunotherapy that is currently used to treat blood cancers and is in clinical trials to treat other cancers as well. This treatment
Transthyretin amyloidosis (ATTR amyloidosis) is a rare but fatal disease marked by clumping and accumulation of mutated, misfolded transthyretin proteins in peripheral nerves and cardiac
A common refrain in science fiction movies is the cautionary statement, “Just because we can doesn’t mean we should.” As new technologies such as CRISPR/Cas9
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
Emails are serviced by Constant Contact. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.